Gilman Hill Asset Management’s GSK GSK Stock Holding History

Gilman Hill Asset Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.75M	Buy	128,768 +7,593	+6%	+$402K	0.92%	42
2026 Q1	$6.69M	Sell	121,175 -5,673	-4%	-$307K	1.01%	39
2025 Q4	$6.22M	Buy	126,848 +3,540	+3%	+$165K	0.98%	41
2025 Q3	$5.32M	Buy	123,308 +4,433	+4%	+$173K	0.83%	55
2025 Q2	$4.56M	Buy	118,875 +49,014	+70%	+$1.87M	0.75%	59
2025 Q1	$2.71M	Buy	69,861 +5,599	+9%	+$205K	0.47%	77
2024 Q4	$2.17M	Sell	64,262 -3,160	-5%	-$114K	0.38%	88
2024 Q3	$2.76M	Buy	67,422 +5,965	+10%	+$244K	0.46%	73
2024 Q2	$2.37M	Buy	61,457 +4,005	+7%	+$168K	0.43%	81
2024 Q1	$2.46M	Buy	57,452 +2,857	+5%	+$118K	0.44%	80
2023 Q4	$2.02M	Sell	54,595 -5,815	-10%	-$209K	0.38%	87
2023 Q3	$2.19M	Sell	60,410 -1,429	-2%	-$50.7K	0.43%	82
2023 Q2	$2.2M	Buy	61,839 +6,085	+11%	+$218K	0.41%	84
2023 Q1	$1.98M	Buy	55,754 +3,911	+8%	+$137K	0.4%	82
2022 Q4	$1.82M	Sell	51,843 -3,606	-7%	-$120K	0.37%	81
2022 Q3	$1.63M	Sell	55,449 -1,246	-2%	-$47.2K	0.38%	86
2022 Q2	$3.08M	Buy	56,695 +829	+1%	+$45.8K	0.66%	46
2022 Q1	$3.04M	Buy	55,866 +4,799	+9%	+$261K	0.69%	44
2021 Q4	$2.81M	Sell	51,067 -776	-1%	-$40.4K	0.63%	42
2021 Q3	$2.48M	Buy	51,843 +3,908	+8%	+$196K	0.63%	52
2021 Q2	$2.39M	Buy	47,935 +32	+0.1%	+$1.54K	0.61%	50
2021 Q1	$2.14M	Buy	47,903 +2,716	+6%	+$123K	0.59%	54
2020 Q4	$2.08M	Buy	45,187 +17,229	+62%	+$791K	0.68%	47
2020 Q3	$1.31M	Sell	27,958 -720	-3%	-$36.1K	0.51%	54
2020 Q2	$1.46M	Sell	28,678 -504	-2%	-$25.9K	0.58%	53
2020 Q1	$1.38M	Buy	29,182 +576	+2%	+$30.7K	0.67%	46
2019 Q4	$1.68M	Buy	28,606 +744	+3%	+$41.4K	0.55%	54
2019 Q3	$1.49M	Sell	27,862 -88	-0.3%	-$4.53K	0.49%	56
2019 Q2	$1.4M	Buy	27,950 +932	+3%	+$46.8K	0.47%	55
2019 Q1	$1.41M	Buy	27,018 +996	+4%	+$49.8K	0.5%	52
2018 Q4	$1.24M	Sell	26,022 -1,332	-5%	-$65.6K	0.52%	53
2018 Q3	$1.37M	Buy	27,354 +1,576	+6%	+$80.1K	0.54%	53
2018 Q2	$1.3M	Buy	25,778 +424	+2%	+$21.4K	0.53%	54
2018 Q1	$1.24M	Buy	25,354 +2,752	+12%	+$128K	0.54%	54
2017 Q4	$1M	Sell	22,602 -80	-0.4%	-$3.7K	0.41%	56
2017 Q3	$1.15M	Buy	22,682 +2,084	+10%	+$106K	0.47%	54
2017 Q2	$1.11M	Buy	20,598 +1,640	+9%	+$87.4K	0.48%	51
2017 Q1	$999K	Buy	18,958 +5,744	+43%	+$291K	0.43%	51
2016 Q4	$636K	Sell	13,214 -3,405	-20%	-$168K	0.23%	79
2016 Q3	$896K	Buy	16,619 +1,593	+11%	+$87.3K	0.35%	60
2016 Q2	$814K	Buy	15,026 +2,074	+16%	+$109K	0.33%	59
2016 Q1	$657K	Buy	12,952 +2,676	+26%	+$133K	0.3%	68
2015 Q4	$518K	Sell	10,276 -1,357	-12%	-$69.2K	0.25%	84
2015 Q3	$559K	Buy	11,633 +4	+0%	+$208	0.29%	72
2015 Q2	$605K	Sell	11,629 -1,720	-13%	-$96.8K	0.29%	70
2015 Q1	$770K	Buy	13,349 +792	+6%	+$45.4K	0.36%	63
2014 Q4	$671K	Sell	12,557 -229	-2%	-$12.8K	0.34%	64
2014 Q3	$735K	Buy	12,786 +3,352	+36%	+$205K	0.4%	61
2014 Q2	$631K	Buy	9,434 +3,744	+66%	+$253K	0.33%	65
2014 Q1	$380K	Buy	5,690 +2,284	+67%	+$154K	0.22%	82
2013 Q4	$227K	Buy	+3,406	New	+$221K	0.15%	103

Other funds holding GSK

Douglas Lane & Associates New York $7.37B AUM 21.9% 1-Year Est. Return

QRG Capital Management Chicago, Illinois $12.1B AUM 44.98% 1-Year Est. Return

Stablepoint Partners Braintree, Massachusetts $723M AUM 29.31% 1-Year Est. Return

CWA Asset Management Group Naples, Florida $3.25B AUM 34.07% 1-Year Est. Return

First Bank & Trust Brookings, South Dakota $680M AUM 25.36% 1-Year Est. Return

Bonness Enterprises Washington, District of Columbia $310M AUM 24.22% 1-Year Est. Return

Redhawk Wealth Advisors Minneapolis, Minnesota $1.02B AUM 35.15% 1-Year Est. Return

InvesTrust Oklahoma City, Oklahoma $260M AUM 25.89% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Tower Trust & Investment Company Davenport, Iowa $165M AUM 28.96% 1-Year Est. Return